Amicus Therapeutics Inc (FOLD)
9.485
-0.10
(-1.09%)
USD |
NASDAQ |
Nov 21, 16:00
9.485
0.00 (0.00%)
After-Hours: 20:00
Amicus Therapeutics Revenue (Quarterly): 141.52M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 141.52M |
| June 30, 2024 | 126.67M |
| March 31, 2024 | 110.40M |
| December 31, 2023 | 115.08M |
| September 30, 2023 | 103.50M |
| June 30, 2023 | 94.50M |
| March 31, 2023 | 86.27M |
| December 31, 2022 | 88.10M |
| September 30, 2022 | 81.69M |
| June 30, 2022 | 80.73M |
| March 31, 2022 | 78.72M |
| December 31, 2021 | 82.15M |
| September 30, 2021 | 79.54M |
| June 30, 2021 | 77.41M |
| March 31, 2021 | 66.40M |
| December 31, 2020 | 70.57M |
| September 30, 2020 | 67.44M |
| June 30, 2020 | 62.35M |
| March 31, 2020 | 60.52M |
| December 31, 2019 | 55.29M |
| September 30, 2019 | 48.77M |
| June 30, 2019 | 44.13M |
| March 31, 2019 | 34.05M |
| December 31, 2018 | 32.64M |
| September 30, 2018 | 20.60M |
| Date | Value |
|---|---|
| June 30, 2018 | 21.31M |
| March 31, 2018 | 16.70M |
| December 31, 2017 | 14.73M |
| September 30, 2017 | 10.87M |
| June 30, 2017 | 7.158M |
| March 31, 2017 | 4.169M |
| December 31, 2016 | 2.831M |
| September 30, 2016 | 2.127M |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | 0.293M |
| June 30, 2014 | 0.475M |
| March 31, 2014 | 0.456M |
| December 31, 2013 | 0.324M |
| September 30, 2013 | 0.039M |
| June 30, 2013 | |
| March 31, 2013 | |
| December 31, 2012 | |
| September 30, 2012 | |
| June 30, 2012 | 10.64M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
55.29M
Minimum
Dec 2019
141.52M
Maximum
Sep 2024
86.44M
Average
81.21M
Median
Revenue (Quarterly) Benchmarks
| Tonix Pharmaceuticals Holding Corp | 2.822M |
| Alnylam Pharmaceuticals Inc | 500.92M |
| Ionis Pharmaceuticals Inc | 133.81M |
| Arbutus Biopharma Corp | 1.339M |
| Krystal Biotech Inc | 83.84M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -6.729M |
| Total Expenses (Quarterly) | 116.72M |
| EPS Diluted (Quarterly) | -0.02 |
| Enterprise Value | 3.005B |
| Gross Profit Margin (Quarterly) | 90.62% |
| Profit Margin (Quarterly) | -4.75% |
| Earnings Yield | -3.58% |
| Operating Earnings Yield | 0.50% |
| Normalized Earnings Yield | -2.947 |